EULAR 2019: Gout gaps call for better education, survey says

German family-owned drugmaker Grünenthal has reported its findings from a pan-European survey on gout at the ongoing EULAR Congress.

The survey, which was supported by 12 international and national patient organizations and included 1,100 gout patients from 14 European countries, found that gout is being diagnosed late and is not controlled effectively or monitored regularly enough.

Despite these significant gaps in the management of the disease, eight out of 10 patients claim they are satisfied with their current treatment.